Enrolling by invitationPhase 2NCT07567274

DMSO Dual-Route Therapy for Refractory Tinnitus in Long-COVID and Post-COVID-19 Vaccine Injury

Studying Primary sclerosing cholangitis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Leading Edge Clinic
Principal Investigator
Scott D Marsland, MS Nursing
Leading Edge Clinic
Intervention
DMSO-based otic solution with betahistine, dexamethasone, and lidocaine(drug)
Enrollment
20 target
Eligibility
18-70 years · All sexes
Timeline
20262027

Study locations (1)

Collaborators

Rebuild Medicine Inc

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07567274 on ClinicalTrials.gov

Other trials for Primary sclerosing cholangitis

Additional recruiting or active studies for the same condition.

See all trials for Primary sclerosing cholangitis

← Back to all trials